Shots:

• The collaboration will assess the combination of Dynavax’s advanced adjuvant- CpG 1018 with Sinovac’s chemically inactivated coronavirus vaccine candidate
• Dynavax’s CpG 1018 is the adjuvant used in HEPLISAV-B- the FDA’s approved vaccine for hepatitis B. It was developed to increase HEPLISAV-B vaccine’s immune response
• CpG 1018 provides a technology and a safety database to accelerating the development of a vaccine against COVID-19. The companies intend the collaboration and prior clinical experience of CpG 1018 enables them to rapidly develop a vaccine

Click here ­to­ read full press release/ article | Ref: Dynavax | Image: CmoCro